|Bid||175.31 x 900|
|Ask||175.63 x 800|
|Day's range||175.47 - 175.71|
|52-week range||89.62 - 176.19|
|Beta (5Y monthly)||1.06|
|PE ratio (TTM)||59.68|
|Earnings date||26 Jan 2021|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||02 Dec 1998|
|1y target est||177.75|
Varian's (VAR) fiscal first-quarter earnings are likely to reflect strength in Halcyon platform.
Varian (NYSE: VAR) has been recognized again as the leader in the annual IMV ServiceTrak™ Radiation Oncology Systems report, ranking first in all nine of the tracked categories. Additionally, Varian's Net Promotor Score (NPS) improved from 78 in 2019 to 85 in 2020—the highest NPS among industry competitors. NPS represents the likelihood a customer would recommend a manufacturer to a colleague.
Varian (VAR) will be coordinating with Yonsei Cancer Center on formulating AI solutions, which are proven to upgrade early detection of cancer.